M
Description
Biotechnology company founded in 2019 in Cambridge, Massachusetts, developing first-in-class antibodies to treat fibrosis in multiple indications (idiopathic pulmonary fibrosis, systemic sclerosis, kidney fibrosis). Backed by Novartis Venture Fund, Pfizer Ventures and Eli Lilly with $105 million financing.